Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Medical Research Council | OTHER_GOV |
| Invicro | OTHER |
Not provided
Not provided
Not provided
The acute effects of cannabis may differ between adolescents and adults. Furthermore, these effects may be tempered by the presence of cannabidiol. This double-blind, placebo-controlled, crossover experiment investigates the acute effects of cannabis (with and without cannabidiol) on subjective effects, behavioural responses and neural functioning in 16-17 year-olds and 26-29 year-olds who regularly use cannabis (0.5-3 days per week).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| THC condition | Experimental | THC condition: Cannabis with delta-9-tetrahydrocannabinol (THC) and no cannabidiol (CBD). 0.107mg/kg of THC. A 75kg person receives 8mg of THC. Route of administration: vaporised and inhaled. Frequency: once. Duration: inhaled in < 18 minutes. |
|
| THC+CBD condition | Experimental | THC+CBD condition: Cannabis with THC and CBD (i.e. THC+CBD condition). 0.107mg/kg of THC and 0.320mg/kg of CBD. A 75kg person receives 8mg of THC and 24mg of CBD. Route of administration: vaporised and inhaled. Frequency: once. Duration: inhaled in < 18 minutes. |
|
| PLA condition | Placebo Comparator | PLA condition: Placebo cannabis with no THC or CBD. Route of administration: vaporised and inhaled. Frequency: once. Duration: inhaled in < 18 minutes. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) | Drug | Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) - inhaled and vaporised cannabis flower |
| Measure | Description | Time Frame |
|---|---|---|
| Psychotomimetic effect | Measured by total Psychotomimetic States Inventory (PSI) score | Measured once, 2 hours after the start of drug administration, on each drug condition |
| Verbal episodic memory | Measured by delayed prose recall performance | Measured once, 2 hours after the start of drug administration, on each drug condition |
| Strength of subjective drug effect | Measured by self-reported 'feel drug effect', rated from 0 (not at all) to 10 (extremely) | Measured 20 minutes after the start of drug administration, on each drug condition |
| Measure | Description | Time Frame |
|---|---|---|
| Self-reported subjective effects | Feel drug effect, like drug effect, dislike drug effect, alert, want to have cannabis, happy, relaxed, anxious, paranoid, mentally impaired, stoned, dry mouth, unmotivated, intensified sensory perception, want to listen to music, want food, want to see friends, rated from 0 (not at all) to 10 (extremely) | Measured -30 minutes, 20 minutes, 30 minutes, 2 hours, and 2 hours & 40 minutes after the start of drug administration, on each drug condition |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University College London | London | WC1E 7HB | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38416223 | Derived | Hall D, Lawn W, Ofori S, Trinci K, Borissova A, Mokrysz C, Petrilli K, Bloomfield MAP, Wall MB, Freeman TP, Curran HV. The acute effects of cannabis, with and without cannabidiol, on attentional bias to cannabis related cues: a randomised, double-blind, placebo-controlled, cross-over study. Psychopharmacology (Berl). 2024 Jun;241(6):1125-1134. doi: 10.1007/s00213-024-06543-7. Epub 2024 Feb 28. | |
| 36750134 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Double-blind, placebo-controlled, crossover experiment with drug condition block randomised and stratified by age-group and gender, such that drug order is counterbalanced.
There are two groups: adolescents (16-17 years old) and adults (26-29 years old). These groups are matched on current cannabis use frequency.
There are three drug conditions: (1) cannabis with delta-9-tetrahydrocannabinol (THC) and without cannabidiol (CBD), (2) cannabis with THC but without CBD, and (3) placebo cannabis without THC and without CBD.
Not provided
Not provided
Double-blind
| Cannabis with THC without CBD | Drug | Cannabis with THC without CBD - inhaled and vaporised cannabis flower |
|
| Placebo cannabis | Drug | Placebo cannabis, without THC and without CBD - inhaled and vaporised |
|
| Functional magnetic resonance imaging (fMRI) measured neural correlates | Reward anticipation and reward feedback, response inhibition, spatial working memory, and resting-state | Measured between 40 minutes and 1 hour & 20 minutes after the start of drug administration, on each drug condition |
| Magnetic resonance spectroscopy | Measuring glutamate levels in the dorsal striatum | Measured 1 hour & 30 minutes after the start of drug administration, on each drug condition |
| Positive and negative syndrome scale | Kay et al. (1987). Higher scores reflect stronger positive and negative symptoms. | Measured 2 hours & 40 minutes after the start of drug administration, on each drug condition |
| Effort-related decision-making (i.e. amotivation) | Measured by the physical effort task ('apple-gathering' task) as described in Husain & Roiser (2018) | Measured 2 hours & 20 minutes after the start of drug administration, on each drug condition |
| Pleasure processing | Measured by subjective liking in response to chocolate, music and cartoons, rated from 0 (not at all) to 10 (extremely), similar to Lawn et al. (2015) | Measured 2 hours & 30 minutes after the start of drug administration, on each drug condition |
| Visual attentional bias to cannabis and food stimuli | Measured by the visual dot-probe task, as described in Morgan et al. (2010) | Measured 2 hours & 10 minutes after the start of drug administration, on each drug condition |
| Heart rate | Measuring heart rate | Measured -30 minutes, 20 minutes, 30 minutes, 2 hours, and 2 hours & 40 minutes after the start of drug administration, on each drug condition |
| Blood pressure | Measuring systolic and diastolic blood pressure. | Measured -30 minutes, 20 minutes, 30 minutes, 2 hours, and 2 hours & 40 minutes after the start of drug administration, on each drug condition |
| Exogenous and endogenous cannabinoid levels in plasma | Measuring THC and CBD and metabolites; and endocannabinoids | Measured -30 minutes, 20 minutes, 30 minutes, and 2 hours & 40 minutes after the start of drug administration, on each drug condition |
| Dissociative states scale | Bremner et al. (1998). Higher scores reflect greater dissociation. | Measured 2 hours & 40 minutes after the start of drug administration, on each drug condition |
| Derived |
| Lawn W, Trinci K, Mokrysz C, Borissova A, Ofori S, Petrilli K, Bloomfield M, Haniff ZR, Hall D, Fernandez-Vinson N, Wang S, Englund A, Chesney E, Wall MB, Freeman TP, Curran HV. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment. Addiction. 2023 Jul;118(7):1282-1294. doi: 10.1111/add.16154. Epub 2023 Feb 26. |
| 36642667 | Derived | Skumlien M, Freeman TP, Hall D, Mokrysz C, Wall MB, Ofori S, Petrilli K, Trinci K, Borissova A, Fernandez-Vinson N, Langley C, Sahakian BJ, Curran HV, Lawn W. The Effects of Acute Cannabis With and Without Cannabidiol on Neural Reward Anticipation in Adults and Adolescents. Biol Psychiatry Cogn Neurosci Neuroimaging. 2023 Feb;8(2):219-229. doi: 10.1016/j.bpsc.2022.10.004. Epub 2022 Oct 28. |
| 35032682 | Derived | Dhami P, Quilty LC, Schwartzmann B, Uher R, Allen TA, Kloiber S, Lam RW, MacQueen G, Frey BN, Milev R, Muller DJ, Strother SC, Blier P, Soares CN, Parikh SV, Turecki G, Foster JA, Rotzinger S, Kennedy SH, Farzan F. Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2023 Feb;8(2):162-170. doi: 10.1016/j.bpsc.2021.12.012. Epub 2022 Jan 13. |
| ID | Term |
|---|---|
| D002189 | Marijuana Abuse |
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C587251 | nabiximols |
| D013759 | Dronabinol |
| D002185 | Cannabidiol |
| ID | Term |
|---|---|
| D002186 | Cannabinoids |
| D013729 | Terpenes |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
Not provided
Not provided